Cognition Therapeutics (CGTX) Operating Expenses (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Operating Expenses data on file, last reported at $8.8 million in Q1 2026.

• Quarterly Operating Expenses fell 35.99% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (down 33.03% YoY) and the FY2025 annual result came in at -$906000.0, down 103.14% from the prior year.
• Operating Expenses rose to $8.8 million in Q1 2026 per CGTX's latest filing, from -$329000.0 in the prior quarter.
• Across five years, Operating Expenses topped out at $15.2 million in Q4 2023 and bottomed at -$329000.0 in Q4 2025.
• The 5-year median for Operating Expenses is $12.6 million (2022), against an average of $10.6 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 141.72%; it then plunged 316.45% in 2025.
• Tracing CGTX's Operating Expenses over 5 years: stood at $12.6 million in 2022, then gained by 20.31% to $15.2 million in 2023, then plunged by 99.0% to $152000.0 in 2024, then plunged by 316.45% to -$329000.0 in 2025, then surged by 2779.94% to $8.8 million in 2026.
• Per Business Quant, the three latest CGTX Operating Expenses figures stand at $8.8 million (Q1 2026), -$329000.0 (Q4 2025), and $6.4 million (Q3 2025).

Peer Comparison